The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Cited by
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Chemogenetics revealed: DREADD occupancy and activation via converted clozapine
Gomez, J. L., Bonaventura, J., Lesniak, W., Mathews, W. B., Sysa-Shah, P., Rodriguez, L. A., Ellis, R. J., Richie, C. T., Harvey, B. K., Dannals, R. F., et al. (2017) · Science · doi:10.1126/science.aan2475 · Cited by 980
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 714
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
Street, J. S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.968 · Cited by 590
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512
Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494
Pharmacology and behavioral pharmacology of the mesocortical dopamine system
Tzschentke, T. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00033-2 · Cited by 481
Doran, A., Obach, R. S., Smith, B. J., Hosea, N. A., Becker, S., Callegari, E., Chen, C., Chen, X., Choo, E., Cianfrogna, J., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001230 · Cited by 443
Modern antipsychotic drugs: a critical overview
Gardner, D. M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041064 · Cited by 422
Weiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1313-x · Cited by 391
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Daniel, D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00090-6 · Cited by 377
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370
Dukart, J., Holiga, S., Rullmann, M., Lanzenberger, R., Hawkins, P. C. T., Mehta, M. A., Hesse, S., Barthel, H., Sabri, O., Jech, R., et al. (2021) · Human Brain Mapping · doi:10.1002/hbm.25244 · Cited by 347
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.35 · Cited by 266
Paliperidone for schizophrenia
Dolder, C., Nelson, M., & Deyo, Z. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070261 · Cited by 254
Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy
Markowitz, J. S., Brown, C. S., & Moore, T. R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17215 · Cited by 208
Bymaster, F. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00146-7 · Cited by 200
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Agelink, M. W., Majewski, T., Wurthmann, C., Lukas, K., Ullrich, H., Linka, T., & Klieser, E. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00003 · Cited by 166
Tauscher, J., Hussain, T., Agid, O., Verhoeff, N. P. L. G., Wilson, A. A., Houle, S., Remington, G., Zipursky, R. B., & Kapur, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1620 · Cited by 159
Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans
Vermeir, M., Naessens, I., Remmerie, B., Mannens, G., Hendrickx, J., Sterkens, P., Talluri, K., Boom, S., Eerdekens, M., van Osselaer, N., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018275 · Cited by 158
Passik, S. D., Lundberg, J., Kirsh, K. L., Theobald, D., Donaghy, K., Holtsclaw, E., Cooper, M., & Dugan, W. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00391-3 · Cited by 154
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Tracing the development of psychosis and its prevention: what can be learned from animal models
Piontkewitz, Y., Arad, M., & Weiner, I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.019 · Cited by 108
Leung, S., Croft, R. J., Baldeweg, T., & Nathan, P. J. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0865-1 · Cited by 81
Olanzapine for intractable nausea in palliative care patients.
Jackson, W. C., & Tavernier, L. (2003) · Journal of Palliative Medicine · doi:10.1089/109662103764978506 · Cited by 78
The potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Margolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61
Powell, S. B., Young, J. W., Ong, J. C., Caron, M. G., & Geyer, M. A. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830dc110 · Cited by 57
Lack of effect of acute dopamine precursor depletion in nicotine-dependent smokers
Casey, K. F., Benkelfat, C., Young, S. N., & Leyton, M. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.02.002 · Cited by 54
Schoretsanitis, G., Spina, E., Hiemke, C., & de Leon, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1549489 · Cited by 50
Berwaerts, J., Cleton, A., Rossenu, S., Talluri, K., Remmerie, B., Janssens, L., Boom, S., Kramer, M., & Eerdekens, M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106914 · Cited by 49
Risperidone Pretreatment Prevents Elevated Locomotor Activity Following Neonatal Hippocampal Lesions
Richtand, N. M., Taylor, B., Welge, J. A., Ahlbrand, R., Ostrander, M. M., Burr, J., Hayes, S., Coolen, L. M., Pritchard, L. M., Logue, A., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300791 · Cited by 45
Luo, M., Wang, X. S., Roth, B. L., Golbraikh, A., & Tropsha, A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400460q · Cited by 37
Rational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29
Carli, M., Calcagno, E., Mainini, E., Arnt, J., & Invernizzi, R. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2066-6 · Cited by 20
Metadata
- Authors
- Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E.
- Venue
- Psychopharmacology
- Published
- 1996-03
- Volume
- 124
- Issue
- 1-2
- Pages
- 57-73
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1979700184
- Cited by
- 1,167
- References
- 3
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.